The FDA has approved Axsome Therapeutics Inc’s (NASDAQ:AXSM) Auvelity (dextromethorphan HBr -bupropion HCl) extended-release tablets for major depressive disorder (MDD) in…
The U.S. Food and Drug Administration (FDA) has approved Axsome Therapeutics’ (NASDAQ: AXSM) lead asset AUVELITY (dextromethorphan HBr -bupropion HCl) extended-release tablets for the treatment of major depressive disorder (MDD) in adults.
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that data from the
The European Medicines Agency (EMA) has validated Aeglea BioTherapeutics Inc’s (NASDAQ:AGLE) marketing application seeking approval for pegzilarginase for the treatment of…
The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ: KRYS) Biologics License Application (BLA) for its lead candidate B-VEC in the treatment of patients with dystrophic epidermolysis bullosa (DEB).
The Elon Musk-led mega-EV company Tesla Inc (NASDAQ: TSLA) announced on Aug. 4 its intention to split its stock just two years after completing another stock split.
With the 3-1 split just a week away, here’s what you need to know about it.